AI Cure is a research tool showing open data. Not medical advice. Discuss with your doctor. Terms

← Trials
🧪

Differentiation of Benign and Malignant Pulmonary Nodules by Volatile Organic Compounds in Human Exhaled Breath

Recruitingn/aAges 18 Years - 80 YearsAllChromX Health
💬

In plain words

What the trial is, and whether it could suit you

The goal of this observational study is to develop an advanced expiratory algorithm model utilizing exhaled breath volatile organic compound (VOC) markers. This model aims to accurately differentiate benign from malignant nodules in individuals harboring pulmonary nodules. The primary objectives it strives to accomplish are: 1. To assess the diagnostic accuracy of an exhaled breath VOC-assisted diagnostic artificial intelligence (AI) model in distinguishing benign and malignant pulmonary nodules. 2. To evaluate the diagnostic effectiveness of an AI model that employs exhaled breath VOC biomakers to identify specific types of malignant nodules, including lung adenocarcinoma, lung squamous cell carcinoma, and small cell lung cancer. 3. To explore and identify key characteristic VOCs combinations that are associated with EGFR site mutations in malignant nodules, further modeling and evalua

Sign in to get the eligibility rules as simple questions to take to your doctor.

📋 Eligibility rules (as published)
Inclusion Criteria: * 18-80 years old; * Pulmonary nodules were detected through low-dose spiral CT, chest CT conventional scan, or high-resolution thin-layer CT examination, with a maximum diameter of 5-30 mm, including solid nodules and ground glass nodules; * Patients require pulmonary nodule resection to define the type of nodule pathology; * The Patients have not yet used any drugs for tumor treatment; * Patients and/or family members are able to understand the research protocol and are willing to participate in this study, providing written informed consent. Exclusion Criteria: * The maximum diameter of pulmonary nodules is greater than 30 mm; * Patients are unable to determine the pathological diagnosis of pulmonary nodules after surgical resection or biopsy; * Patients with recurrent lung cancer; * Patients who have undergone lung transplantation or lobectomy; * Individuals who currently or have a history of malignant tumors; * Patients in the acute phase of inflammation or in need of intensive care in the above selected disease groups; * Individuals with severe liver and kidney dysfunction; * Mental illness patients (such as severe dementia, schizophrenia, severe depression, manic depressive psychosis, etc.); * Confirmed HIV patients; * Pregnant or lactating women; * Patients or family members are unable to understand the conditions and objectives of this study. * The patient is unwilling or unable to personally sign the informed consent form.
💊

What it tests

  • Gas chromatography-mass spectrometry(GC-MS) and micro Gas Chromatography-photoionisation detector (μGC-PID) system
📍

Where

15 sites
Peking Union Medical College Hospital
Beijing, China
First People's Hospital of Foshan
Foshan, China
The First Affiliated Hospital of Guangzhou Medical University
Guangzhou, China
Liwan District Central Hospital
Guangzhou, China
Guangzhou Development Zone Hospital
Guangzhou, China
Huangpu District Chinese Medicine Hospital
Guangzhou, China
Huangpu District Hongshan Street Community Health Service Center
Guangzhou, China
Huangpu District Jiufo Street Community Health Service Center
Guangzhou, China

…and 7 more on ClinicalTrials.gov.

🤝 Taking part is your choice, and you can leave at any time. Only the trial team can confirm you are eligible — always decide together with your own doctor.
🛡️

AI Cure shows public evidence (Open Targets, ClinicalTrials.gov, PubMed, openFDA, DepMap, AlphaFold) with its source, and AI summaries that cite it — not medical advice and not a cure. Treatment decisions belong with your doctor. Research ideas are shared only with approved researchers and labs, who can test them. In an emergency call your local emergency number (112 in India and Europe, 911 in the US). AI Cure Terms of Use · Privacy